MYGN
Myriad Genetics, Inc.
Diagnostics & Research · Healthcare · United States
6.67
close · 2026-10-29
value
82
cheaper than peers82
quality
12
stronger fundamentals12
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| price to sales | 0.91× | 95 |
| price to book | 2.10× | 91 |
| forward P/E | 35.54× | 33 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 32.8% | 71 |
| operating margin | -21.4% | 25 |
| return on equity | -23.5% | 22 |
| revenue growth | -20.8% | 5 |
4 of 4 measures available
Facts
| market cap | $638M |
| free cash flow | -$46.1M |
| employees | 2,700 |
| first trade | 1995-10-06 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-07-30 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.95 | -1.41 | -3.18 | -1.39 |
| free cash flow | -$25.6M | -$38.4M | -$184.2M | -$151.6M |
| net income | -$365.9M | -$127.3M | -$263.3M | -$112.0M |
| revenue | $824.5M | $837.6M | $753.2M | $678.4M |
| unusual items | -$319.4M | -$35.5M | -$112.8M | -$16.9M |